Astec Lifesciences Ltd
NSE:ASTEC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
827.75
1 458.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Astec Lifesciences Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | IN |
| Market Cap | 20.8B INR |
| Net Margin |
-28%
|
| Country | US |
| Market Cap | 42.2B USD |
| Net Margin |
4%
|
| Country | CA |
| Market Cap | 32.4B CAD |
| Net Margin |
3%
|
| Country | US |
| Market Cap | 15.7B USD |
| Net Margin |
19%
|
| Country | SA |
| Market Cap | 53.8B SAR |
| Net Margin |
33%
|
| Country | CN |
| Market Cap | 99.6B CNY |
| Net Margin |
34%
|
| Country | CL |
| Market Cap | 10.9B USD |
| Net Margin |
35%
|
| Country | US |
| Market Cap | 8.3B USD |
| Net Margin |
3%
|
| Country | IN |
| Market Cap | 624.5B INR |
| Net Margin |
22%
|
| Country | RU |
| Market Cap | 7.4B USD |
| Net Margin |
15%
|
| Country | US |
| Market Cap | 7.3B USD |
| Net Margin |
35%
|
Astec Lifesciences Ltd
Glance View
Astec LifeSciences Ltd. engages in the manufacture and sale of agrochemicals and pharmaceutical intermediates. The company is headquartered in Mumbai, Maharashtra and currently employs 506 full-time employees. The company went IPO on 2009-11-25. The firm operates through the Agrochemicals segment. The company manufactures a range of fungicides, insecticides, herbicides and intermediates for its global customers. The Company’s product and intermediates include triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans and heterocyclic sulfonyl chlorides. The company has two multipurpose production sites at Mahad.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Astec Lifesciences Ltd's most recent financial statements, the company has Net Margin of -27.8%.
You don't have any saved screeners yet
